Search Results
Mar 26, 2026, 07:00 ET METALLA REPORTS RECORD 2025 FINANCIAL RESULTS HIGHLIGHTING PORTFOLIO INFLECTION AND FUTURE CASH FLOW GROWTH
TSXV: MTANYSE American: MTAVANCOUVER,
More news about: Metalla Royalty & Streaming Ltd.
Mar 25, 2026, 08:00 ET AT&T and Boldyn Networks complete cellular service in additional tunnel segments of the MTA's 4/5 and G lines
fully committed to turning on service for riders as fast as possible and the MTA has been an exceptional partner in keeping work moving quickly."What's next: Boldyn is continuing to coordinate work with the MTA to expand their DAS cellular network to additional underground areas, including
More news about: Boldyn Networks
Mar 19, 2026, 13:05 ET A Cúpula Global de Turismo Médico e Seguros retorna como o evento de negociação de portas fechadas mais influente do setor
Better by MTA recebem um passe de inscrição gratuito, sujeito à disponibilidade.Por mais de 15 anos, a Cúpula Global de Turismo e Seguros Médicos tem servido
More news about: Medical Tourism Association
Mar 19, 2026, 12:21 ET La Cumbre Mundial de Turismo Médico y Seguros vuelve como el evento de negociación a puerta cerrada más influyente de la industria
Better by MTA reciben un pase de registro gratuito, sujeto a disponibilidad.Durante más de 15 años, la Cumbre Mundial de Turismo Médico y Seguros ha servido
More news about: Medical Tourism Association
Mar 19, 2026, 10:09 ET The Global Medical Tourism & Insurance Summit Returns as the Industry's Most Influential Closed-Door Deal-Making Event
Better by MTA members receive a complimentary registration pass, subject to availability.For more than 15 years, the Global Medical Tourism & Insurance
More news about: Medical Tourism Association
Mar 19, 2026, 09:45 ET The Global Medical Tourism & Insurance Summit Returns as the Industry's Most Influential Closed-Door Deal-Making Event
Better by MTA members receive a complimentary registration pass, subject to availability.For more than 15 years, the Global Medical Tourism & Insurance
More news about: Medical Tourism Association
Mar 18, 2026, 06:00 ET IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
topoisomerase-1 (TOP1) antibody-drug conjugate (ADC); IDE574, a potent dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7; and IDE892, an MTA-cooperative inhibitor of PRMT5. The company is currently conducting Phase 1 clinical studies to evaluate safety, tolerability, PK and efficacy of these
More news about: IDEAYA Biosciences, Inc.
Mar 12, 2026, 18:15 ET Ethica Wines Celebrates 10th Anniversary with Artwork Honoring Company Manifesto
an audacious campaign of "bombing" clean NYC subway trains, embedding his mark on the city's moving canvases. In the early '90s, GIZ initiated the 'MTA' (Most Talked About) street-bombing campaign, which saw his and his crew's work spread across the five boroughs of New York City. This period of intense
More news about: Ethica Wines
Mar 11, 2026, 06:00 ET Municipal Data & Power Launches Global Data & Energy Infrastructure Platform Following Approval of Two Initial AI Data Centers with Power Grids in Nigeria - Preps RFP for MDP USA Factory and Micro Power Grid Sites
infrastructure modernization, housing, business start-ups, manufacturing, community economic development projects, transportation systems including the MTA, job creation, and education initiatives.Unlike traditional development models that rely primarily on tax incentives, MDP's framework proposes
More news about: Municipal Data & Power
Mar 09, 2026, 09:15 ET Antimony Emerges as Strategic Growth Play in $4B+ Critical Minerals Market
could remain a small but strategically important growth market within the broader critical minerals sector.American Antimony Reports First MTA Results: 30.3% Sb Average Head Grade Produces 63% Sb Concentrate at 97% Recovery - American Antimony Corporation, operating as Xtra Energy Corporation (OTCID:
More news about: Market News Updates
Mar 09, 2026, 09:00 ET Antimony Demand Surges as Military Tech Boom Pushes Market Toward $4 Billion
emerging as one of the most important—and closely watched—critical materials in the modern defense economy.American Antimony Reports First MTA Results: 30.3% Sb Average Head Grade Produces 63% Sb Concentrate at 97% Recovery - American Antimony Corporation, operating as Xtra Energy Corporation (OTCID:
More news about: Market News Updates
Mar 09, 2026, 06:00 ET IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
Potential best-in-class profile, including ~1,400-fold selective binding to MTA-PRMT5 versus SAM-PRMT5 complexes, and single-digit nanomolar potency in MTAP-deleted cell linesIDE892 is being evaluated as a monotherapy agent in MTAP-deleted solid tumors, including NSCLC and
More news about: IDEAYA Biosciences, Inc.
Mar 01, 2026, 19:30 ET XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), and ATG-042 (oral PRMT5-MTA inhibitor).Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring "2+1" bivalent binding for low expressing
More news about: Antengene Corporation Limited
Feb 26, 2026, 08:00 ET Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
material transfer agreements (MTA) with pharmaceutical companies, including major global pharmaceutical companies, who are evaluating the potential of Matrix-M in their portfolio of vaccine products.In the fourth quarter of 2025, Novavax signed a new MTA with a large pharmaceutical
More news about: Novavax, Inc.
Feb 25, 2026, 16:07 ET OUTFRONT Media Reports Fourth Quarter And Full Year 2025 Results
by higher transit franchise costs, including higher guaranteed minimum annual payments to the New York Metropolitan Transportation Authority (the "MTA").Selling, General and Administrative expenses ("SG&A") of $111.2 million increased $1.6 million, or 1.5%, due primarily to higher professional
More news about: OUTFRONT Media Inc.
Feb 24, 2026, 19:30 ET Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring "2+1" bivalent binding for low-expressing
More news about: Antengene Corporation Limited
Feb 12, 2026, 16:15 ET Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update
treatment that includes the anti-PD-1 agents, Keytruda® or Opdivo®.Technology Development:Under a Material Transfer Agreement (MTA), Stavro is evaluating the compatibility of the Hemopurifier with their SLAMB system, a simplified blood treatment platform. We believe this research
More news about: Aethlon Medical, Inc.
Feb 11, 2026, 17:00 ET METALLA ANNOUNCES PRELIMINARY 2025 GEO DELIVERIES, RECORD ANNUAL REVENUES AND CORPORATE UPDATES
MTANYSE AMERICAN: MTAVANCOUVER,
More news about: Metalla Royalty & Streaming Ltd.
Feb 04, 2026, 17:31 ET Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
designation for the same indication.In May 2025, Elicera Therapeutics AB announced that it had entered into a Material Transfer Agreement (MTA) with University Hospital Tübingen in Germany. Under the agreement, the company's oncolytic virus candidates ELC-100 and ELC-201 will be included in
More news about: DelveInsight Business Research, LLP
Feb 03, 2026, 16:01 ET AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
overexpression was completed.AMG 193AMG 193 is a first-in-class small molecule methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor.A Phase 2 study of AMG 193 is ongoing patients with methylthioadenosine phosphorylase
More news about: Amgen
Feb 01, 2026, 23:30 ET Wego and Visit Malta Advance Partnership into Its Second Year in MENA to Inspire Travel to Malta
private sector in national planning and development of the industry. The Malta Tourism Authority (MTA) has a diverse role, but one which in essence is all about creating and fostering relationships. The MTA is the tourism industry's regulator and motivator, its business partner, the country's brand promoter,
More news about: Wego
Feb 01, 2026, 23:30 ET Wego and Visit Malta Advance Partnership into Its Second Year in MENA to Inspire Travel to Malta
private sector in national planning and development of the industry. The Malta Tourism Authority (MTA) has a diverse role, but one which in essence is all about creating and fostering relationships. The MTA is the tourism industry's regulator and motivator, its business partner, the country's brand promoter,
More news about: Wego
Jan 27, 2026, 20:00 ET ヘイマックス、ピークXVパートナーズ主導のもと、APAC全域での旅行およびロイヤルティにおける製品開発と地域拡大を加速させるため、1100万米ドルのシリーズAを獲得
XVは、同地域での19年間にわたる運用を通じて、13のファンドで約90億米ドルの資金を運用するまでに成長し、400社以上に投資してきました。これまでに33件の新規株式公開（IPO）と複数のM&Aの成功を実現しています。詳しくはこちらをご覧ください：https://protect.checkpoint.com/v2/r01/___http:/www.peakxv.com___.YzJ1OndlY29tbXVuaWNhdGlvbnM6YzpvOjIzMTk3NmNkNzA4MTA0MzJhODc3MWI0Mz
More news about: HeyMax
Jan 20, 2026, 13:05 ET Michael Mangione named HNTB's New York office leader
Department of Design and Construction East Side Coastal Resiliency Project, statewide programs for the New York State Department of Transportation, and key MTA projects including the Second Avenue Subway Phase 2, Systemwide Open Road Tolling Conversion and the Bronx Whitestone and Henry Hudson Bridge Approaches
More news about: HNTB Corporation
Jan 15, 2026, 20:00 ET Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
ATG-037 (oral CD73 inhibitor) , ATG-101 (PD-L1 × 4-1BB bispecific antibody) , ATG-031 (CD24-targeting macrophage activator) , and ATG-042 (oral PRMT5-MTA inhibitor).Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring "2+1" bivalent binding for low-expressing
More news about: Antengene Corporation Limited